Peter Thuss-Patience
彼得·图斯-帕提安斯
MD
Professor of Medicine; Head of Upper GI Oncology, Charité Comprehensive Cancer Center, Berlin医学教授，柏林夏里特综合癌症中心上消化道肿瘤科主任
👥Biography 个人简介
Peter Thuss-Patience, MD is Professor of Medicine and Head of Upper GI Oncology at the Charité Comprehensive Cancer Center, Berlin. He is a leading European expert in the perioperative and palliative treatment of gastric and gastroesophageal junction cancer. Dr. Thuss-Patience played a central role in the development and clinical validation of the FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) regimen as perioperative treatment for resectable gastric and GEJ adenocarcinoma, contributing to the landmark FLOT4 trial that demonstrated FLOT's superiority over ECF/ECX and established it as the European standard of care. He has been an investigator in multiple pivotal trials evaluating ramucirumab, trastuzumab, and immunotherapy combinations in advanced gastric cancer. Dr. Thuss-Patience also contributed to early evidence establishing irinotecan monotherapy as a second-line option in gastric cancer. His work spans the continuum from early resectable disease through metastatic settings and he serves on ESMO and German gastric cancer guideline committees.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLOT Perioperative Regimen for Resectable Gastric/GEJ Cancer
Contributed to the development and phase II/III evaluation of FLOT4 perioperative chemotherapy for resectable gastric and GEJ adenocarcinoma, demonstrating that FLOT achieved superior pathologic complete response rates and overall survival versus ECF/ECX, establishing FLOT as the European perioperative standard.
Irinotecan as Second-Line Therapy in Gastric Cancer
Conducted pivotal randomized trials establishing irinotecan monotherapy as an active and tolerable second-line option in advanced gastric cancer, providing the first high-quality European evidence for post-first-line chemotherapy in this disease and influencing guideline recommendations.
Ramucirumab Clinical Development in Gastric Cancer
Participated as a European site investigator in ramucirumab trials (REGARD, RAINBOW) in gastric and GEJ cancer, contributing patient accrual and data supporting VEGFR2 inhibition in second-line treatment and the current approval of ramucirumab monotherapy and combination with paclitaxel.
Perioperative Biomarkers and Pathologic Response Assessment
Led correlative studies examining the relationship between pathologic tumor regression grade, circulating biomarkers, and survival in patients receiving perioperative FLOT-based chemotherapy, developing tools for early assessment of treatment benefit in resectable gastric cancer.
Representative Works 代表性著作
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4)
The Lancet (2019)
Landmark FLOT4 phase III trial demonstrating FLOT superiority over ECF/ECX in resectable gastric/GEJ adenocarcinoma, establishing FLOT as the perioperative standard in Europe.
Irinotecan versus best supportive care as second-line therapy in gastric cancer: A randomised phase II/III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
European Journal of Cancer (2011)
Randomized trial demonstrating irinotecan prolongs survival over best supportive care in second-line gastric cancer, providing European evidence for second-line chemotherapy.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)
The Lancet (2010)
Participated in the ToGA trial establishing trastuzumab plus chemotherapy as standard first-line therapy for HER2-positive advanced gastric/GEJ cancer.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD)
The Lancet (2014)
Phase III REGARD trial establishing ramucirumab monotherapy as the first anti-angiogenic agent to demonstrate survival benefit in second-line advanced gastric/GEJ cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 彼得·图斯-帕提安斯 的研究动态
Follow Peter Thuss-Patience's research updates
留下邮箱，当我们发布与 Peter Thuss-Patience（Charité – Universitätsmedizin Berlin）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment